Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Papillomavirus Infections 1Atypical Squamous Cells of the Cervix 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × epigallocatechin gallate × Gynecologic × Clear all
NCT07572396 2026-05-14

Phase II Study of Dysplasixâ„¢ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

Amplexd Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia, Papillomavirus Infections, Atypical Squamous Cells of the Cervix

Data powered by HemOnc (CC BY 4.0) Colophon âš¡